NFKB1 and Bloom syndrome: CONCLUSIONS: Our findings suggest that CAI may have therapeutic value in BS by targeting the core pathogenic NF-κB/MAPK signaling axes and reducing cytokines production, which highlights CAI as a new potential medication for BS.